期刊
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY
卷 14, 期 5, 页码 513-522出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCEP.120.008540
关键词
atrial fibrillation; clinical trial; left atrium; medical imaging; pulmonary vein
资金
- National Institutes of Health (NIH) [U01HL089709, U01HL089786, U01HL089907, U01HL089645]
- St Jude Medical Foundation and Corporation
- BiosenseWebster, Inc
- Medtronic, Inc
- Boston Scientific Corp.
The CABANA trial included a prospective imaging substudy to investigate changes in left atrial and pulmonary vein dimensions in atrial fibrillation patients undergoing catheter ablation versus drug therapy. While changes in left atrial and PV dimensions did not predict the primary study endpoint, reductions in left atrial volume index and mean PV diameter were associated with a decreased risk of AF recurrence. Ablation patients showed more significant atrial structural changes compared to drug therapy patients, suggesting a relationship between structural features and AF generation.
Background: The CABANA trial (Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation) was a randomized, prospective trial of left atrial catheter ablation versus drug therapy for treatment of atrial fibrillation (AF). As part of CABANA, a prospective imaging substudy was conducted. The main objectives were to describe the patterns of changes in the dimensions of the left atrium and pulmonary veins (PVs), and the relationship between these changes with treatment assignment and clinical outcomes. Methods: Computed tomography or magnetic resonance imaging was acquired at baseline and follow-up in 121 ablation (median follow-up 101 days) and 85 drug patients (median follow-up 97 days). Left atrial volume index, mean PV ostial diameter, and ostial diameters of each PV separately were computed. We examined the relationship between the change from baseline to follow-up with subsequent clinical outcomes (composite of death, disabling stroke, serious bleeding, or cardiac arrest [CABANA primary end point], total mortality or cardiovascular hospitalization, first AF recurrence after the 90-day blanking period, first AF/atrial flutter/atrial tachycardia after the 90-day blanking period) using Cox proportional-hazards models. Results: The median (25th to 75th) change from baseline for left atrial volume index was -7.8 mL/m(2) (-16.4 to 0.2), ablation arm and -3.5 mL/m(2) (-11.4 to 2.6), drug therapy arm. The left atrial volume index decreased in 52.9% of ablation patients versus 40.0% of drug therapy patients. Change for mean PV was -2.7 mm (-4.2 to -1.3) in the ablation arm versus -0.1 mm (-1.5 to 0.8) in the drug therapy arm. Changes in left atrium and PV dimensions had no consistent relationship with the risk of developing the study primary end point. Reductions in left atrial volume index, and in mean PV diameter were associated with decreased risk of AF recurrence. Conclusions: Ablation patients demonstrated more frequent and larger atrial structural changes compared with drug patients. These changes suggest a critical relationship between structural features and AF generation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据